Abstracts & Posters

 

IASP 2020

Beyond the Numbers: A Validations Study of the Pain Tolerability Question

JOA 2020

Efficacy of Tanezumab, a Nerve Growth Factor Antibody, in Japanese Patients With Chronic Low Back Pain: A 56-Week Treatment, Celecoxib-Controlled, Study

EULAR 2020

Efficacy of Subcutaneous Tanezumab for the Treatment of Chronic Low Back Pain: An Analysis of Brief Pain Inventory-Short Form Scores from a Randomized, Placebo- and Tramadol-Controlled, Phase 3 Trial

AAN 2020

Subcutaneous Tanezumab Versus Placebo or Tramadol in Patients with Chronic Low Back Pain: 16-Week Efficacy and Safety Results from a Phase 3 Study

NeuPSIG 2019

Assessment of the Efficacy and Safety of Vixotrigine in Participants With Lumbosacral Radiculopathy: Results of a Randomized, Placebo-Controlled Trial

EFIC 2019

Subcutaneous Tanezumab Versus Tramadol for Chronic Low Back Pain: Efficacy and Safety Results From a 56-Week Phase 3 Study With a 24-Week Follow Up Period